, Volume 77, Issue 16, pp 1811–1816 | Cite as

Elsulfavirine: First Global Approval

  • Zaina T. Al-SalamaEmail author
AdisInsight Report


Elsulfavirine (Elpida®) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. In June 2017, elsulfavirine received its first global approval in Russia for the treatment of HIV-1 infections in combination with other antiretroviral medicines. Other formulations of this drug are also being evaluated in preclinical and phase II studies for the treatment of HIV infections and/or pre-exposure and post-exposure prophylaxis. This article summarizes the milestones in the development of elsulfavirine leading to this first approval in HIV-1 treatment.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Zaina T. Al-Salama is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at


  1. 1.
    Viriom Inc. Viriom obtains first market approval of elsulfavirine (Elpida®) for treatment of HIV-1 infection in Russia [media release]. 2017. Accessed 19 Sep 2017.
  2. 2.
    Viriom Inc. HIV/AIDS: definition, prevention, treatment, diagnosis, causes. 2017. Accessed 19 Sep 2017.
  3. 3.
    Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16:1–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Viriom Inc. Elpida (elsulfavirine) capsules: Russian prescribing information. 2017. Accessed 19 Sep 17.
  5. 5.
    Viriom Inc. Viriom pipeline. 2017. Accessed 19 Sep 2017.
  6. 6.
    Viriom Inc. Viriom announces receipt of funding from the Skolkovo Foundation, ChemRar and Torrey Pines Investment to develop Elpida(Rm), a novel preventive and long- acting treatment of HIV/AIDS [media release]. 2016. Accessed 19 Sep 2017.
  7. 7.
    Viriom Inc. Viriom expands global licensing agreement with Roche for innovative compound development for HIV treatment [media release]. 2013. Accessed 19 Sep 2017.
  8. 8.
    Viriom Inc. Roche and Viriom sign license agreement for innovative drugs against HIV [media release]. 2009. Accessed 19 Sep 2017.
  9. 9.
    ChemDiv Inc. Viriom selects ChemDiv to develop HIV program [media release]. 2009. Accessed 19 Sep 2017.
  10. 10.
    Kravchenko A, Orlova-Morozova E, Nagimova F, et al. Safety and antiviral effect of elpida (VM-1500), a novel NNRTI (+truvada) in treatment-naïve HIV-1 infected patients [poster PE7/4]. In: 15th European AIDS Conference. 2015.Google Scholar
  11. 11.
    Murphy RL, Kravchenko A, Orlova-Morozova E, et al. Elsulfavirine as compared to efavirenz in combination with TDF/FTC: 48-week study [abstract no. 452LB plus poster 2637]. In: Conference on Retroviruses and Opportunistic Infections (CROI). 2017.Google Scholar
  12. 12.
    US Department of Health and Human Services. AIDSinfo: VM-1500. 2017. Accessed 19 Sep 2017.
  13. 13.
    Viriom Inc. Research and development of innovative formulations of the Russian drug (new-generation NNRTI) and new treatment regimens to improve compliance and treatment efficacy for patients with HIV infection [presentation]. In: Conference Biotech RusFrance 2016: new Russian-French cooperation opportunities in biotechnology. 2016.Google Scholar
  14. 14.
    Ratanasuwan W, Werarak P, Koryakova A, et al. Pharmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients [abstract no. LBPE20 plus poster]. In: 20th International AIDS Conference. 2014.Google Scholar
  15. 15.
    Bichko V, Rogovoy B, Koryakova A, et al. Pre-clinical pharmacokinetics of elsulfavirine/VM1500A long acting injectable formulations [abstract no. WEPEA0190 plus poster]. In: 9th IAS Conference on HIV Science [IAS2017]. 2017.Google Scholar
  16. 16.
    Kravchenko A, Orlova-Morozova E, Shimonova T, et al. The efficacy and safety of elpivirine as part of a 24–48-week antiretroviral therapy regimen versus an efavirenz-containing regimen. Epidemiol Infect Dis. 2016;5:73–80.Google Scholar
  17. 17.
    Ratanasuwan W, Werarak P, Murphy RL, et al. A randomized, placebo-controlled, double-blind study of VM-1500 in HIV-naive patients [abstract no. 544LB]. Top Antivir Med. 2014;22(e1):262–3.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations